摘要
胃肠间质瘤（gastrointestinal stromal tumor，GIST）的概念是近年才明确的，目前已经基本弄清GIST在分子水平的发病过程．并且CD117成为常规的免疫组化检查手段。既往这些肿瘤常被归类为平滑肌瘤、平滑肌肉瘤或平滑肌母细胞瘤。1983年．Mazur和Clark首次发现这组肿瘤既无平滑肌分化、又无神经源性分化的抗原表达和超微结构，将其命名为“胃肠间质瘤”。但这类全新概念的实体肿瘤却在生物学特性上差异很大。还有许多问题需要探讨和研究。现仅就现有资料较缺乏的GIST流行病学情况以及临床工作中所关心的治疗问题谈谈看法。
Gastrointestinal stromal tumor （GISTs） are a new recognized tumor entity. The incidence increases with time for the greater awareness of GISTs. Latest repertes of the epidemiology of GISTs have been collected and sorted. Besides, it is still a controversy on the management of GISTs. While surgical en-bloc resection is the treatment of choice, Imatinib is still optimal for patients with recurrent or metastatic GISTs. Preliminary promising effects have been showed on neo-adjuvant and postoperational adjuvant therapies. Imatinib-resistant GISTs become common and more targeted medication have been investigated and tested.
出处
《中华胃肠外科杂志》
CAS
2007年第1期8-10,共3页
Chinese Journal of Gastrointestinal Surgery
